NUVL Quote, Financials, Valuation and Earnings

Edgewise Therapeutics, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of --. Nuvalent, Inc.'s return on equity of -41.59% beat Edgewise Therapeutics, Inc.'s return on equity of -32.79%.

Nuvalent, Inc. has a consensus price target of $143.94, signalling upside risk potential of 44.63%. On the other hand Edgewise Therapeutics, Inc. has an analysts' consensus of $40.17 which suggests that it could grow by 34.88%. Given that Nuvalent, Inc. has higher upside potential than Edgewise Therapeutics, Inc., analysts believe Nuvalent, Inc. is more attractive than Edgewise Therapeutics, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edgewise Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Edgewise Therapeutics, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Edgewise Therapeutics, Inc. quarterly revenues of --. Nuvalent, Inc.'s net income of -$118.7M is lower than Edgewise Therapeutics, Inc.'s net income of -$50.2M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Edgewise Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus -- for Edgewise Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Glaukos Corp. has a net margin of -- compared to Nuvalent, Inc.'s net margin of -93.39%. Nuvalent, Inc.'s return on equity of -41.59% beat Glaukos Corp.'s return on equity of -25.22%.

Nuvalent, Inc. has a consensus price target of $143.94, signalling upside risk potential of 44.63%. On the other hand Glaukos Corp. has an analysts' consensus of $134.79 which suggests that it could grow by 36.23%. Given that Nuvalent, Inc. has higher upside potential than Glaukos Corp., analysts believe Nuvalent, Inc. is more attractive than Glaukos Corp..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.259%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Glaukos Corp. quarterly revenues of $143.1M. Nuvalent, Inc.'s net income of -$118.7M is higher than Glaukos Corp.'s net income of -$133.7M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 11.15x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Neurocrine Biosciences, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of 19.08%. Nuvalent, Inc.'s return on equity of -41.59% beat Neurocrine Biosciences, Inc.'s return on equity of 17%.

Nuvalent, Inc. has a consensus price target of $143.94, signalling upside risk potential of 44.63%. On the other hand Neurocrine Biosciences, Inc. has an analysts' consensus of $178.04 which suggests that it could grow by 37.11%. Given that Nuvalent, Inc. has higher upside potential than Neurocrine Biosciences, Inc., analysts believe Nuvalent, Inc. is more attractive than Neurocrine Biosciences, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neurocrine Biosciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.196%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neurocrine Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Neurocrine Biosciences, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Neurocrine Biosciences, Inc. quarterly revenues of $805.5M. Nuvalent, Inc.'s net income of -$118.7M is lower than Neurocrine Biosciences, Inc.'s net income of $153.7M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Neurocrine Biosciences, Inc.'s PE ratio is 27.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 4.65x for Neurocrine Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Nuvalent, Inc.'s net margin of -246.76%. Nuvalent, Inc.'s return on equity of -41.59% beat Vanda Pharmaceuticals, Inc.'s return on equity of -47.32%.

Nuvalent, Inc. has a consensus price target of $143.94, signalling upside risk potential of 44.63%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $15.50 which suggests that it could grow by 75.94%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Nuvalent, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Nuvalent, Inc..

Nuvalent, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.303%.

Nuvalent, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuvalent, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nuvalent, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $57.2M. Nuvalent, Inc.'s net income of -$118.7M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$141.2M. Notably, Nuvalent, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuvalent, Inc. is -- versus 2.40x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.